Search

Displaying results 5381 - 5390 of 8010 in total
  1. Drug

    MLN0415

    go.drugbank.com/drugs/DB05183
    Experimental

    MLN0415 is a novel, small molecule IKK2 inhibitor, discovered by Millennium scientists. … Because inflammatory proteins play a critical role in inflammation and drive the inflammatory response to disease, controlling these proteins may prevent or slow disease progression.

  2. Drug

    Oprelvekin

    go.drugbank.com/drugs/DB00038
    ApprovedInvestigationalWithdrawn

    Oprelvekin works by stimulating megakaryocytopoiesis and thrombopoiesis. … Oprelvekin, the active ingredient in Neumega®, is recombinant Interleukin-11 (IL-11), which is produced in Escherichia coli (E. coli) by recombinant DNA technology.

  3. Drug

    Alamifovir

    go.drugbank.com/drugs/DB06368
    Experimental

    Alamifovir is an antiviral agent specific for HBV.

  4. Drug

    Viralym-C

    go.drugbank.com/drugs/DB17975
    Investigational

    It was granted FDA orphan designation in January 2017 and investigated for the treatment of CMV infection.[A260291, L47241] … Viralym-C is an investigational T-cell immunotherapy developed by ViraCyte. It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes.

  5. Drug

    Chlorcyclizine

    go.drugbank.com/drugs/DB08936
    Approved

    Chlorcyclizine is a first generation phenylpiperazine class antihistamine used to treat urticaria, rhinitis, pruritus, and other allergy symptoms. Chlorcyclizine also has some local anesthetic, anticholinergic, and antiserotonergic prope...

    Categories: Antihistamines for Systemic Use
  6. Drug

    SYNB1020

    go.drugbank.com/drugs/DB17667
    Investigational

    It was initially designed to convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016;[L45988] however, the manufacturer … SYNB1020 is an engineered strain of _Escherichia coli_ Nissle 1917 developed by Synlogic Inc.

  7. Drug

    Propyl alcohol

    go.drugbank.com/drugs/DB03175
    Approved

    A colorless liquid made by oxidation of aliphatic hydrocarbons that is used as a solvent and chemical intermediate.

  8. Drug

    Azelnidipine

    go.drugbank.com/drugs/DB09230
    Investigational

    It is currently being studied for post-ischemic stroke management [L1380]. … It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan.

  9. Drug

    IR502

    go.drugbank.com/drugs/DB06463
    Experimental

    IR502 (Zorcell) is a potential treatment for psoriasis.

  10. Drug

    GX-19 Vaccine

    go.drugbank.com/drugs/DB15891
    Investigational

    As of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels for safety and efficacy[A219758,L16488]. … The GX-19 vaccine is a DNA vaccine created by Genexine, Inc. Company in Gyeonggi, Korea[A219758].